President of Americas, Zimmer Biomet
Search every verified Mark Bezjak interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Mark Bezjak, President of Americas at Zimmer Biomet, appeared on a December 2024 episode of "160 Studios" hosted by Joe Mullings. During the interview, Bezjak discussed his 16-year tenure at the company, attributing his longevity to the opportunity to "differentiate musculoskeletal care" and the people and leadership at the organization. He stated that he took his current role because of CEO Ivon, citing the need to "work at that pace" and "think creatively and outside the box" to change the delivery of musculoskeletal care. Bezjak described the company's focus on advancing technology, including its PIQ platform for collecting post-operative data, and predicted a "seismic shift" in orthopedics over the next 24 to 36 months with the integration of sensored technology, interconnectivity, and predictive analytics. Bezjak noted that 20% of knee replacement patients are not satisfied with their outcomes, and he said the company's innovation is driven by understanding the patient journey from pre-operative care through rehab. He emphasized Zimmer Biomet's goal of being "the boldest medtech company" and its shift from a focus on metal and plastic implants to a solutions-based organization. Bezjak also highlighted the company's partnerships in building ambulatory surgery centers and its ability to hyperfocus on musculoskeletal health as an efficiency advantage over competitors.
“The mission of the organization is to alleviate pain and improve the quality of life for people around the world, and it's not just the implant while it's a big piece of who we are, but the advancement of the technology to take it to that next level for a multitude of end users whether it's the patient, the physician,...”
“Joint replacements are probably one of the most successful procedures but it's not good enough; 20% of patients who get knee replacements are not happy with their outcomes, and the reason for innovation is to understand that complete journey from the time the patient walks in the door through rehab and beyond.”
“With our PIQ platform, you collect data post-op and now you've got the complete continuum of care for that patient, allowing identification of what's happening through the journey—good, bad, benefits the patient, the physician, payers, and providers.”
“Patients are now asking for PIQ with our physicians because they want to be active participants; they want to know how they're measuring up against others, creating a social environment where they can compare themselves and understand where they are in their recovery journey.”
“It started with leadership and the bold statement of being the boldest Medtech company on the planet; we knew 20% of total joints were problematic and nobody answered why, and understanding why drove innovation from the very top down.”
“Orthopedics has been the last frontier compared to cardiac and neuro implants, but over the last four or five years, that has started to pivot with the advancement and adoption of technology, and to continue at that pace, we have to run fast and keep up with the energy and passion of our leadership.”
“The next 24 to 36 months will see a seismic shift in orthopedics with the integration of sensored technology, interconnectivity, and predictive analytics, enabling personalized patient management based on pre-, intra-, and post-operative data.”
“The shift is happening from hospital or acute care settings into outpatient settings for joint replacements, improving clinical outcomes and efficiency, and Zimmer Biomet is leading the front with partnerships to build ambulatory surgery centers and advanced robotic platforms.”
“Most other orthopedic companies don't have the ability to hyperfocus on a single industry; Zimmer Biomet's focus on musculoskeletal health allows it to provide solutions in newer ways without competing with other divisions, which is a significant efficiency advantage.”
“To be the boldest Medtech company, we must continue adoption of technology, maintain clinical outcomes, and embrace diverse thinking; we are at a tipping point where metal and plastic implants evolve into a solutions-based organization.”
Subscribe to Our Channel Here https://www.youtube.com/MullingsGroup --------------- LinkedIn: ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Mark Bezjak.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →